The short answer
Many people with CLL start with watchful waiting, because trials found no survival benefit from treating early-stage disease immediately. When treatment is needed, IGHV and TP53 or del(17p) results steer the choice between BTK inhibitors, venetoclax and chemoimmunotherapy.
Watchful waiting is standard for early, symptom-free CLL: a meta-analysis of randomized trials found no survival benefit for immediate over delayed therapy.
Treatment is usually triggered by rising white cell counts, worsening anemia or low platelets, growing nodes or spleen, fevers, drenching night sweats or weight loss.
Two results shape the first treatment: IGHV mutation status, and TP53 change or del(17p), which tends to resist standard chemotherapy.
NCI lists ibrutinib, acalabrutinib and zanubrutinib as BTK-type inhibitors, venetoclax as a BCL2 inhibitor, and rituximab or obinutuzumab as infused antibodies.
Choose how you want to understand this
The full explanation.
Start with whether you need treatment at all
Many people with CLL are diagnosed early and feel well. For them, watchful waiting is standard: regular blood counts and visits, with treatment starting only if the disease becomes active. This is not neglect. Studies have not shown a survival benefit to starting treatment before it is needed.
What triggers treatment
Your team watches for specific signs. These include rapidly rising white blood cell counts, worsening anemia, or low platelets. Growing lymph nodes or spleen also count, as do fevers, drenching night sweats, or weight loss. Reaching one of these usually starts the conversation about treatment.
Two key results that shape drug choice
Before choosing a first treatment, your team should check two results. One is your IGHV mutation status. The other is TP53 gene changes, or a missing piece of chromosome 17, called del(17p). CLL with a TP53 change tends to resist standard chemotherapy. That steers treatment toward drugs that do not depend on that gene.
Targeted pills over chemotherapy
Treatment for CLL has shifted heavily toward targeted pills instead of older-style chemotherapy. BTK inhibitors include ibrutinib, acalabrutinib, and zanubrutinib. They block a growth signal CLL cells depend on, and are taken daily, often long-term. Venetoclax blocks a different survival protein, called BCL2. It is often combined with an antibody drug like obinutuzumab, for a fixed length of time rather than indefinitely. Monoclonal antibodies such as rituximab and obinutuzumab, given by infusion, are often paired with these pills.
When chemotherapy or transplant still matter
Chemoimmunotherapy is still used in some situations, particularly for certain lower-risk, IGHV-mutated CLL. Stem cell transplant is reserved for a small number of people with high-risk or treatment-resistant disease. CAR T-cell therapy reprograms your own immune cells. It is being studied for CLL that has stopped responding to other treatments.
Weighing benefits and harms
BTK inhibitors are daily pills. They avoid many classic chemotherapy side effects. But they carry their own risks, including irregular heartbeat, high blood pressure, and bleeding. That is why your team may check your heart rhythm before you start.
Venetoclax needs a careful, slow dose ramp-up. It can rapidly kill many cancer cells at once. That risk is called tumor lysis syndrome, and it needs close monitoring, sometimes with a hospital stay for the first doses.
What to ask your team
- Do I actually need treatment now, or does watchful waiting fit my case?
- What are my IGHV and TP53 (or del(17p)) results?
- Why was this specific drug, or drug combination, chosen for me?
- What monitoring does starting venetoclax or a BTK inhibitor require?
- What symptoms should prompt an urgent call?
When to get help sooner
- Call 911 or go to an emergency department if bleeding will not stop, you vomit blood, or your stools are black and tarry. BTK inhibitors raise bleeding risk. Do the same for a seizure, sudden confusion, or a collapse.
- Call your care team the same day if the thermometer reads 100.4°F (38°C) or higher, or you shake with chills. CLL itself lowers your antibody levels, and a BTK inhibitor or venetoclax adds to that, so a fever is followed up rather than watched.
- Treat that same fever as an emergency, not a same-day call, if you are on chemoimmunotherapy, or in the ramp-up of venetoclax with obinutuzumab. Those regimens can drop your neutrophils hard, and at that point a fever needs antibiotics within the hour. Ring the 24-hour haematology number the moment you see the reading; if nobody answers, go to an emergency department and tell them your neutrophils may be low.
- Call your care team the same day if your heartbeat feels fast, pounding, or irregular, or if you get chest discomfort or new breathlessness. BTK inhibitors can bring on an irregular rhythm.
- Call your care team the same day if you are in the first weeks of venetoclax and you pass much less urine than usual, your urine turns dark, or you get muscle cramps, nausea, or vomiting. These can be signs of tumor lysis syndrome.
- Call your care team within a day or two if you bruise without injury, bleed from the gums, or get nosebleeds that are new for you.
- Call your care team within a day or two if one lymph node starts growing faster than the rest, or drenching night sweats and unexplained weight loss return.
Sources
Words to know
Tap any term to see what it means.
Common questions
Why might I be told to wait rather than start treatment?
Many people with CLL are diagnosed early and feel well. For them, watchful waiting is standard: regular blood counts and visits, with treatment starting only if the disease becomes active. This is not neglect. Studies have not shown a survival benefit to starting treatment before it is needed.
What would trigger starting treatment?
Your team watches for rapidly rising white blood cell counts, worsening anemia, or low platelets. Growing lymph nodes or spleen also count, as do fevers, drenching night sweats, or weight loss. Reaching one of these usually starts the conversation about treatment.
Which test results decide which drug I get?
Two should be checked before a first treatment. One is your IGHV mutation status. The other is TP53 gene changes, or a missing piece of chromosome 17 called del(17p). CLL with a TP53 change tends to resist standard chemotherapy, which steers treatment toward drugs that do not depend on that gene.
Have pills replaced chemotherapy for CLL?
Largely, though not entirely. Treatment has shifted heavily toward targeted pills: BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib, taken daily and often long-term, and venetoclax, which blocks a survival protein called BCL2 and is usually given for a fixed length of time. Chemoimmunotherapy is still used in some situations, particularly for certain lower-risk, IGHV-mutated CLL.
What are the main risks of these newer drugs?
BTK inhibitors avoid many classic chemotherapy side effects but carry their own risks, including irregular heartbeat, high blood pressure and bleeding. That is why your team may check your heart rhythm before you start. Venetoclax needs a careful, slow dose ramp-up because it can rapidly kill many cancer cells at once, a risk called tumor lysis syndrome, which needs close monitoring and sometimes a hospital stay for the first doses.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this guide into a short list for your care team.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-11 what this meansLast updated: 2026-08-18Next planned review: 2027-01-22
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share